The incidence of gastroenteropancreatic neuroendocrine tumors (GEP-NET) has continued to rise. As a result, therapeutic options for patients with advanced disease have expanded and become more heterogeneous. This review maps the evolving drug-treatment landscape for advanced GEP-NET by summarizing evidence-based progress across established and emerging systemic therapies and by assessing implications for clinical practice.
Somatostatin analogues remain a foundational systemic approach for many patients with advanced GEP-NET. The review presents the role of somatostatin analogue therapy within the broader treatment armamentarium, discussing evidence-based advances and how these agents fit into current clinical strategies. Somatostatin analogues are described as a core method alongside newer modalities.
Targeted therapy is identified as a central pillar in the management of advanced GEP-NET. The article systematically reviews the recent evidence supporting targeted agents and situates their current clinical use. Targeted approaches are framed within the context of the expanding therapeutic options for these tumors and are compared conceptually with other systemic modalities.
Cytotoxic chemotherapy continues to have a role in advanced GEP-NET management. The review outlines where chemotherapy fits among available treatments and summarizes the evidence-based progress that informs its application. Chemotherapy is discussed in relation to tumor biology, patient selection, and integration with other systemic approaches.
Immunotherapy is covered as one of the evolving drug strategies for advanced GEP-NET. The review summarizes the state of evidence for immunotherapy and examines considerations for its clinical use in this patient population. Immunotherapy is discussed alongside targeted agents, chemotherapy, and other systemic options as investigators and clinicians explore its role.
Peptide receptor radionuclide therapy (PRRT) is highlighted as a major therapeutic modality for advanced GEP-NET. The article reviews evidence-based developments in PRRT and places this approach among the core methods available to treat advanced disease. PRRT is discussed with attention to its clinical integration and evolving indications.
The review emphasizes several key challenges that currently complicate clinical decision-making for advanced GEP-NET. These include optimizing the sequence of available treatments, strategies to overcome or delay the development of drug resistance, and the urgent need for validated biomarkers to guide individualized therapy. These challenges are presented as focal points for both clinical practice and research priorities.
Based on clinical practice experience, the authors propose expert viewpoints on future research and therapeutic directions. Emphasis is placed on rational drug combination strategies to improve outcomes, pursuit of novel therapeutic agents, and systematic exploration of new approaches in clinical trials. These perspectives aim to stimulate investigation into ways to enhance efficacy and manage resistance.
The review concludes with a call for advancement of precision treatment models in advanced GEP-NET. Building on the current evidence for somatostatin analogues, targeted therapy, chemotherapy, immunotherapy, and PRRT, the authors advocate development of individualized treatment paradigms informed by biomarkers and resistance mechanisms. Future work is framed around integrating combination strategies and novel therapies into precision frameworks to better tailor systemic treatment for patients with advanced disease.
This article provides a structured overview of the drug-treatment landscape for advanced GEP-NET, summarizing evidence-based progress across multiple systemic modalities and identifying practical clinical challenges. It presents expert opinions and outlines future directions focused on combination approaches, development of new therapies, and movement toward precision medicine models. Details such as specific trial outcomes, drug names, dosing, and biomarker data were not reported in the abstract and would require consultation of the full text for more granular information.